Oxford University genetic analysis spinout Genomics agrees to use its technology to work collaboratively with healthcare company Eisai in its drug discovery process.
Genomics, a spinout from Oxford University, has entered into a collaborative agreement with UK-based healthcare company Eisai.
Genomics has developed an analytical platform for gene sequence analysis and interpretation, and through the agreement with Eisai it will use this to help with Eisai’s drug discovery process.
Nadeem Sarwar, director of the IHGx Research Unit that will be working with Genomics, said: “Genomics’ founders are internationally recognised leaders in the analysis and interpretation of human genetic data. This collaboration is another indication of Eisai’s commitment to leveraging genomic knowledge to accelerate the discovery and development of impactful new medicines.”
John Colenutt, chief executive of Genomics, said: “Genomics is excited to be working with one of the world’s leading research and development-based pharmaceutical companies in the rapidly growing area of genomic analysis. This exciting new area promises to potentially make a positive difference to medicine.”
Genomics recently received a grant from the NHS of £2m ($3m) in March 2013 to continue the development of its analytical platform. It also raised £10.3m in its series A funding round in November 2014.